Investment Thesis
P3 Health Partners exhibits severe financial distress with negative stockholders equity (-$155.2M), critically impaired liquidity (0.24x current ratio), and persistent negative operating cash flow (-$91.2M), despite extraordinary 2751% revenue growth. The company is technically insolvent with liabilities exceeding assets, and at current burn rates faces acute solvency risk without substantial capital infusion.
Strengths
- Exceptional revenue growth of 2751% YoY suggests successful merger integration or market expansion
- Net losses improving 54.2% YoY indicates trajectory toward profitability
- Significant revenue base of $1.5B provides scale if operational leverage can be achieved
Risks
- Negative stockholders equity of -$155.2M indicates technical insolvency and negative book value
- Critical liquidity crisis with current ratio of 0.24x and only $25M cash against $796.9M liabilities
- Negative operating cash flow of -$91.2M and negative free cash flow indicate unsustainable cash burn
- Long-term debt of $228.4M cannot be supported by negative equity base
- Operating margin of -18.5% with -10.1% net margin shows business model not yet viable at scale
Key Metrics to Watch
- Operating cash flow trajectory toward positive territory
- Path to positive operating income and net profitability
- Debt restructuring or equity capital raise to address insolvency
- Liquidity position and covenant compliance with lenders
Financial Metrics
Revenue
1.5B
Net Income
-147.9M
EPS (Diluted)
$-45.26
Free Cash Flow
-91.4M
Total Assets
656.6M
Cash
25.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-18.5%
Net Margin
-10.1%
ROE
N/A
ROA
-22.5%
FCF Margin
-6.3%
Balance Sheet & Liquidity
Current Ratio
0.24x
Quick Ratio
0.24x
Debt/Equity
N/A
Debt/Assets
121.4%
Interest Coverage
N/A
Long-term Debt
228.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T07:48:19.081072 |
Data as of: 2025-12-31 |
Powered by Claude AI